Contrast media in patients with kidney disease: An update

ABSTRACT
Concern for contrast-induced acute kidney injury (CI-AKI) or nephrogenic systemic fibrosis may lead to withholding important studies from patients with kidney disease. However, the actual risk or even the existence of these conditions has recently been called into question. The truth probably lies somewhere in the middle.

KEY POINTS
The risk of CI-AKI appears to be highest in patients with the lowest kidney function, but the overall risk is lower than initially thought.

In the absence of an equivalent alternate study, iodinated contrast studies that are thought to be crucial to the care of patients with kidney disease should not be withheld out of concern for CI-AKI.

Volume expansion with isotonic fluid appears to be the only intervention with a possible benefit in preventing CI-AKI. This is recommended in high-risk patients unless they are clinically volume-overloaded.

With the highly stable class II gadolinium-based contrast agents, the risk of nephrogenic systemic fibrosis appears to be extremely low and as such safe even for patients with advanced, predialysis kidney disease.

End-stage kidney disease patients on dialysis do require a hemodialysis treatment immediately after gadolinium administration.

CONTRAST-INDUCED acute kidney injury (CI-AKI) and nephrogenic systemic fibrosis (NSF) have been 2 of the most feared adverse effects of iodinated contrast media for computed tomography (CT) and gadolinium-based contrast media for magnetic resonance imaging (MRI), respectively. Newer and safer contrast agents and, perhaps, better patient selection and prophylactic measures have ameliorated those risks. Recently, some authors have suggested that NSF has been eradicated, while others question whether CI-AKI is an actual entity.

This review presents and evaluates the data around CI-AKI and NSF and critically highlights the most recent practice guidelines.

IODINATED CONTRAST AND ‘RENALISM’
Iodinated contrast media are commonly used in modern medicine both intravenously with CT studies and arterially during angiographic procedures. Among the possible adverse effects is acute kidney injury, first reported in the 1950s in patients undergoing intravenous pyelography.1 In the 1980s, larger series of cases of acute kidney injury following coronary angiography were reported, and the term contrast-induced nephropathy was coined.2 With growing attention, it was said to be one of the most common causes of hospital-acquired acute kidney injury,3 contributing significantly to incident chronic kidney disease, end-stage kidney disease, and death.4

Early publications defined contrast-induced nephropathy as an increase in creatinine of 0.5 mg/dL or more, or a 25% increase from baseline within 2 to 5 days of exposure.

In 2012, the Kidney Disease Improving Global Outcomes Working Group suggested
Contrast and the Kidney

CI-AKI and defined it as a 50% increase in creatinine from baseline within 7 days of exposure or a 0.3 mg/dL increase within 48 hours. CI-AKI is now the accepted terminology to describe kidney injury precipitated by iodinated contrast media.

Presentation
CI-AKI usually presents within 24 to 48 hours of exposure to iodinated contrast media, with elevation in creatinine and, rarely, oliguria. The creatinine level peaks by 3 to 5 days and usually returns to baseline by 7 to 10 days. Sediment analysis shows granular casts and tubular epithelial cells, and the fractional excretion of sodium is usually low.

Risk factors include chronic kidney disease, diabetes, proteinuria, volume depletion, and concomitant exposure to other nephrotoxins. Procedure-related factors include higher-osmolality contrast media, higher volume given, multiple administrations of iodinated contrast media, and intra-arterial administration with first-pass effect.

The diagnosis is clinical, and it is prudent to rule out other causes of acute kidney injury, in particular, atheroembolic kidney disease in patients undergoing angiography with iodinated contrast media. While the true incidence of atheroembolic kidney disease compared with that of CI-AKI in this situation is not known, supporting evidence comes from reports demonstrating a correlation between the risk of acute kidney injury and atheroma burden, and a lower risk with radial than with femoral angiographic procedures. This disease has a very different clinical course but is commonly misdiagnosed as CI-AKI.

Pathophysiological basis
The pathophysiological basis for CI-AKI is still not completely understood, but direct and indirect mechanisms have been suggested.

Iodinated contrast media are directly toxic to the tubular epithelial cells, leading to loss of polarity (loss of channel restriction to either luminal or basolateral membranes) and eventual apoptosis and necrosis. Elevated blood osmolality due to the contrast media, increased viscosity of the luminal fluid, and free radical formation have also been implicated in direct toxicity.

Deranged hemodynamics underlie the indirect adverse effects of iodinated contrast media, with a brief initial vasodilatory state followed by pronounced and sustained vasoconstriction. Prolonged vasoconstriction, which appears to be mediated through alterations in endothelin, nitric oxide, adenosine, and prostaglandin levels, eventually leads to medullary ischemia. Tubuloglomerular feedback has also been postulated as an explanation for the drop in glomerular filtration rate observed in CI-AKI.

Is it all a myth?
Over the past decade, a number of large epidemiologic studies suggested that acute kidney injury following exposure to iodinated contrast media is not necessarily caused by the contrast media. Some reports even questioned whether it is a real disease. This has sparked much debate and led to newer names for the phenomenon, including postcontrast acute kidney injury and contrast-associated acute kidney injury (Table 1). The rationale of these new definitions is to eliminate the causality associated with the term CI-AKI.

Whether one believes CI-AKI is real or a myth, this debate is not merely theoretical because conclusions drawn have significant implications for the care of our patients who have
chronic kidney disease. For example, Chertow et al\textsuperscript{12} reported an inappropriately low rate of cardiac angiographic procedures in patients who have chronic kidney disease. Presumably, procedures were withheld out of concern for CI-AKI. They coined the term “renalism” to indicate the perhaps inappropriate attention to the kidneys while ignoring the bigger picture. Although it is not yet reported, one could presume the notion of avoidance may encompass all contrast-enhanced CT studies in the chronic kidney disease population.

Those who question the diagnosis of CI-AKI point to studies reporting similar rates of acute kidney injury in patients undergoing contrast-enhanced CT compared with those undergoing an unenhanced study. Davenport et al\textsuperscript{13} used a 1:1 propensity matching algorithm and retrospectively reviewed over 17,000 patients who underwent contrast-enhanced CT or unenhanced CT. In patients whose estimated glomerular filtration rate (eGFR) was less than 30 mL/min/1.73 m\textsuperscript{2}, the rate of acute kidney injury was significantly higher in those exposed to contrast (36.4\% vs 19.4\%, odds ratio 2.96, 95\% confidence interval 1.22–7.17). In those with eGFRs of 30 to 59 mL/min/1.73 m\textsuperscript{2} rates were numerically higher with contrast than without contrast, but the difference did not reach statistical significance, and rates were the same with or without contrast in those with eGFRs of 60 or higher.

McDonald et al\textsuperscript{14} and, more recently, Hinson et al\textsuperscript{15} performed similar large epidemiologic propensity-controlled studies showing no difference in rates of acute kidney injury between contrast recipients and those who underwent unenhanced CT. Notably, both studies demonstrated no difference regardless of the definition of acute kidney injury or eGFR stratification. However, patients with eGFRs less than 45 mL/min/1.73 m\textsuperscript{2} were significantly underrepresented in these studies, accounting for only 5\% to 10\% of participants, with some studies completely excluding patients whose creatinine was above 4 mg/dL.\textsuperscript{15}

Does that mean that CI-AKI does not exist? We believe that would be an erroneous conclusion. Despite the complex algorithms used in the propensity matching, a selection bias remains as to who undergoes contrast CT and who does not. Clinicians’ perceptions of risks and consequently their decisions to give or withhold contrast cannot be ascertained from retrospective analyses. In addition, prevention strategies, or lack thereof, are not accounted for in these large database-driven studies. Moreover, as stated previously, patients with severely decreased eGFR, who are at highest risk of CI-AKI, were underrepresented in the propensity score studies.

However, the risks of CI-AKI are probably overstated. Initial descriptive studies were mostly uncontrolled, and rates of acute kidney injury were based mostly on ICD codes with little adjudication as to the cause. This would ultimately inflate the rates of acute kidney injury attributed to the iodinated contrast media.\textsuperscript{16,17} In addition, changing practices, such as prophylaxis, minimizing exposure, and the development of less toxic, lower-osmolar iodinated contrast media have probably played an important role in reducing the rates of CI-AKI.

Nevertheless, CI-AKI remains real. A recent meta-analysis with more than 1,500 patients undergoing peripheral angiography found a higher incidence of acute kidney injury with iodinated contrast media than with carbon dioxide contrast (11\% vs 4\%, respectively).\textsuperscript{18} In addition, our group recently published a propensity-matched study evaluating rates of acute kidney injury in patients with stage 3 or 4 chronic kidney disease undergoing coronary angiography, contrast-enhanced CT, or nonenhanced CT.\textsuperscript{19} Postcontrast acute kidney injury was noted in 27\%, 24\%, and 24\% of patients, respectively. All cases of acute kidney injury were then adjudicated by 2 nephrologists through chart review to ascertain the cause. They found that the incidence of CI-AKI was 16.5\% in the coronary angiography group and 12.5\% in the contrast-enhanced CT group.

Therefore, despite the lack of conclusive data, CI-AKI remains very much a real entity, although the incidence is lower than originally thought.

The evidence, or lack of evidence, for preventive strategies

The evidence regarding strategies to prevent CI-AKI is far from satisfying. Hiremath and
CONTRAST AND THE KIDNEY

Velez\textsuperscript{16} described it as “a proliferation of small, underpowered trials, often with interventions that were poorly thought out” and said that “subsequent meta-analyses have spawned meta-confusion.” With that in mind, we will try to critically evaluate some of the proposed prophylactic interventions.

Volume expansion

Solomon et al\textsuperscript{20} first reported volume expansion with 0.45% saline to be effective in preventing CI-AKI. Mueller et al,\textsuperscript{21} analyzing 1,620 patients, reported a lower incidence of acute kidney injury with periprocedural use of isotonic saline than with 0.45% saline.

Although hydration has become the accepted standard, the recent AMACING trial challenged its role in preventing CI-AKI. Nijsen et al\textsuperscript{22} randomized 660 patients undergoing contrast-enhanced procedures to undergo volume expansion with 0.9% normal saline or no volume expansion. The latter was found to be noninferior to saline, but the overall rates were low. Notably, patients with an eGFR less than 30 mL/min/1.73 m\textsuperscript{2} were excluded from the study.

More recently, Timal et al\textsuperscript{23} performed a randomized multicenter trial in 523 patients with stage 3 chronic kidney disease undergoing contrast-enhanced CT. Randomization to no hydration was noninferior to prehydration with bicarbonate in terms of postcontrast acute kidney injury, with event rates of 2.7% vs 1.5% respectively (relative risk 1.7, 95% CI 0.5–5.9). Noninferiority was also shown on subgroup analyses based on age, eGFR (30–44 vs 45–60 mL/min/1.73 m\textsuperscript{2}) alone or in combination with risk factors including diabetes. However, the event rate in this trial was lower than in previous trials, and therefore, caution should be used with interpreting the results.

Pharmacotherapy

Acetylcysteine. The acetylcysteine story mirrors that of bicarbonate: a multitude of small studies followed by a series of meta-analyses yielding conflicting results. However, 2 studies over the past few years should settle this discussion for good: the Coronary and Peripheral Vascular Angiography (ACT) trial,\textsuperscript{25} with 2,308 patients undergoing an intravascular angiographic procedure randomized to acetylcysteine vs placebo, and the previously mentioned PRESERVE trial.\textsuperscript{24} Both trials showed no difference in rates of acute kidney injury between the acetylcysteine and placebo groups.

Statins have been postulated to reduce the risk of CI-AKI because of their pleiotropic anti-inflammatory and antioxidant effects, which help stabilize plaque. There have been many conflicting studies, with recent meta-analyses suggesting a possible benefit in patients undergoing coronary angiography.\textsuperscript{10} Whether this benefit is due to prevention of CI-AKI or atheroembolic kidney disease is not clear. Most patients who undergo coronary angiography ultimately receive high-dose statin therapy anyway, making this a moot point.

Other interventions, including vitamin C, high-flow oxygen, and ischemic preconditioning are promising but the evidence remains lacking.

In summary, volume expansion with isotonic saline appears to be the only intervention with a possible benefit in preventing CI-AKI. This is probably important in patients deemed to be at intermediate to high risk (Table 2). Acetylcysteine has no role as a prophylactic measure, and bicarbonate-based fluids do not appear to offer an added benefit beyond volume expansion. Other preventive measures
include using low- or iso-osmolar contrast media with the lowest necessary total dose.

We also advocate withholding nonsteroidal anti-inflammatory drugs, diuretics, angiotensin-converting enzyme inhibitors, and angiotensin II receptor blockers in high-risk patients, acknowledging that the data in that regard are insufficient.

Figure 1 shows our approach when patients with chronic kidney disease require iodinated contrast media.

Note that we generally include nonanuric patients undergoing hemodialysis or peritoneal dialysis in our high-risk category, and unless they are clinically hypervolemic, we recommend prophylaxis to preserve residual kidney function. A reanalysis of the Canada-USA (CANUSA) peritoneal dialysis study\(^26\) elegantly demonstrated that being able to produce as little as 250 mL of urine per day was associated with a 36% lower relative risk of death in peritoneal dialysis patients.

Although the data are less robust, this observation likely applies to hemodialysis patients as well, thus underscoring our recommendation for prophylaxis.\(^27\) We emphasize that the goal of hydration in this nonanuric dialysis population is not to make them hypervolemic, and as such, hydration should be forgone in overtly volume-overloaded patients.

The ideal hydration protocol for prevention remains uncertain, and various volume-expansion algorithms have been suggested using fixed or weight-adjusted regimens. Our practice is to give 1 to 1.5 mL per kg per hour starting 1 hour before and continuing for 6 hours after exposure to iodinated contrast media.

Updated recommendations

In response to the changing evidence, the American College of Radiology and the National Kidney Foundation released a joint consensus statement this year\(^28\) on the use of intravenous iodinated contrast media in patients with kidney disease. Key points are presented in Table 2.

### TABLE 2

<table>
<thead>
<tr>
<th>Consensus statement</th>
<th>Authors’ comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>The risk of contrast-induced acute kidney injury is substantially less than the risk of contrast-associated acute kidney injury, but the actual risk remains uncertain. However, necessary contrast-enhanced CT without an alternative should not be withheld.</td>
<td>We believe this statement should be extrapolated to patients in whom coronary angiographic procedures are deemed necessary.</td>
</tr>
<tr>
<td>Patients at risk for contrast-induced acute kidney injury include those with recent acute kidney injury or those with eGFR &lt; 30 mL/min/1.73 m(^2) (including nonanuric dialysis patients).</td>
<td>Age, diabetes, hypertension, and proteinuria are absent from the risk classification. We believe patients with an eGFR &lt; 45 mL/min/1.73 m(^2), particularly those with the above noted risk factors, should also be considered at increased risk.</td>
</tr>
<tr>
<td>Prophylaxis with intravenous isotonic saline is indicated for patients with eGFR &lt; 30 mL/min/1.73 m(^2) not undergoing dialysis and in patients with acute kidney injury.</td>
<td>We believe that prophylaxis is also warranted in nonanuric patients on hemodialysis or peritoneal dialysis to preserve residual kidney function. Careful attention to volume status is required to avoid hypervolemia.</td>
</tr>
<tr>
<td>Prophylaxis should be individualized for high-risk patients with eGFR between 30 and 44 mL/min/1.73 m(^2).</td>
<td>We support prophylaxis in this population, particularly in the presence of traditional risk factors (diabetes, hypertension, proteinuria).</td>
</tr>
<tr>
<td>Prophylaxis is not indicated for patients with stable eGFR ≥ 45 mL/min/1.73 m(^2).</td>
<td>We concur that the risk of contrast-induced acute kidney injury in this population is low.</td>
</tr>
</tbody>
</table>

ACR = American College of Radiology; CT = computed tomography; eGFR = estimated glomerular filtration rate; NKF = National Kidney Foundation

Based on information in Davenport et al, reference 28.
CONTRAST AND THE KIDNEY

Authorities and radiology societies were quick to react to the crisis of gadolinium-induced NSF. Despite decades of research on iodinated contrast and kidney injury, many questions are yet to be answered. What is the exact mechanism of CI-AKI? What is its true incidence with intravenous vs arterial administration? What significance, if any, does CI-AKI carry?

In our aforementioned study,19 cases adjudicated to be CI-AKI carried no mortality risk, with an overall survival rate similar to that in patients who did not have acute kidney injury. Adjudication is key. We need clear definitions that capture CI-AKI clearly and distinctly from all the potential noise associated with other causes of postcontrast acute kidney injury.

The concept of “renalism” has not only led to fewer angiographic procedures being performed in the chronic kidney disease population,13 it probably also underlies the reason why patients with advanced chronic kidney disease were underrepresented in the observational cohorts described above. Studies need to target this high-risk cohort to better delineate the risks and better establish the utility, or futility, of the currently practiced prophylactic measures. Additional work is clearly needed.

GADOLINIUM-INDUCED NEPHROGENIC SYSTEMIC FIBROSIS

NSF is a debilitating and often-fatal fibrosing disease characterized by skin thickening and organ fibrosis.29 It was first reported in 15 dialysis patients in San Diego in the year 2000.30 However, the relationship between NSF and the use of gadolinium as contrast during MRI remained obscure for a long time, finally being suggested 6 years later in Europe.31

The postulated mechanism was the deposition of toxic free gadolinium molecules in the tissues12 with subsequent increases in circulating fibrocytes,13 an increase in the expression

Figure 1. Our approach to chronic kidney disease patients requiring iodinated contrast media.
of transforming growth factor beta 1,34 and release of proinflammatory and profibrotic cytokines.35 Eventually, gadolinium was detected by electron microscopy on a skin biopsy specimen, specifically in areas of calcium phosphate deposition in blood vessels.36

By 2009, the disease was well established, and the US Food and Drug Administration (FDA) had received over 500 reports, most of them from the United States37 and Denmark.38 In response to this crisis, the authorities and radiology societies were quick to react. In 2007, both the FDA39 and the European Medicine Agency40 issued warnings highlighting the risk of NSF associated with the use of gadolinium-based contrast agents. The American College of Radiology,41 European Society of Urogenital Radiology,42 and other radiology societies published guidelines and recommendations on how to use gadolinium-based contrast agents, particularly in patients with kidney disease.

Gadolinium agents that have a linear molecular shape pose a higher risk, and their use was contraindicated in patients with acute and severe chronic kidney disease with eGFRs less than 30 mL/min/1.73 m², as well as in patients on dialysis. Additionally, evidence that gadolinium-based contrast agents are removed with dialysis43 prompted clinicians to change their clinical practice by offering dialysis to patients with advanced kidney dysfunction who were exposed to these agents. As a result of those measures, the number of cases of NSF was drastically reduced. The last reported case in the United States dates back to 2010, and the last report in the world was in 2012 (Figure 2).44

Classification of gadolinium-based contrast agents
Gadolinium-based contrast agents have been used since the 1980s and were initially thought to have an excellent safety profile.45 This led to their liberal and preferential use compared with iodine-based agents, particularly in patients with reduced kidney function.46 However, their incriminating role in NSF highlighted their potential toxicity.

Gadolinium-based contrast agents share...
CONTRAST AND THE KIDNEY

It is generally accepted that groups I and III should be avoided in patients with advanced chronic kidney disease.

Risk of NSF today

The guidelines set by the FDA and the radiology societies were undoubtedly effective in curbing the disease and eventually eliminating it. A recent review of 639 patients with biopsy-proven NSF from 173 articles estimated that the risk of NSF per million exposures had decreased from 2.07 before 2008 to 0.028 afterward.50

Most cases were associated with exposure to group I agents. However, those guidelines were applied to all gadolinium-based contrast agents without considering their stability or association with NSF. The downside of this approach was the denial of clinically indicated contrast-enhanced MRI in patients with severe kidney disease, with a subsequent potential real (though unmeasured) harm resulting from misdiagnosis or diagnostic delay.51

In recent years, evidence has been accumulating as to the safety of group II agents. A recent systematic review and meta-analysis evaluated the pooled risks of NSF in patients with stage 4 or 5 chronic kidney disease receiving a group II gadolinium-based contrast agent.52 The authors analyzed 16 studies with 4,931 patients who received group II agents. The pooled risk of NSF was 0% (upper bound of 95% CI 0.07%). Thus, they estimated the per-patient risk of NSF from receiving group II gadolinium-based contrast agents in stage 4 or 5 chronic kidney disease to be less than 0.07%. This risk is much smaller than that of contrast-induced nephropathy in patients with advanced chronic kidney disease who receive iodinated contrast,53 and thus argues for a better safety profile of contrast-enhanced MRI using group II agents. In fact, the risk appears to be comparable to that of developing a severe allergic reaction to contrast agents, which is estimated at 0.04% for low-osmolality iodinated contrast agents54 and 0.002% to 0.006% for group II agents.55

Updated recommendations

On the basis of accumulating evidence,56–60 the recent guidelines of the American College of Radiology,41 the European Society of Urogenital Radiology,61 and the Canadian As-

<table>
<thead>
<tr>
<th>TABLE 3</th>
<th>Cyclic</th>
<th>Linear</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ionic</td>
<td>Gadoteric acid</td>
<td>Gadobenate dimeglumine</td>
</tr>
<tr>
<td></td>
<td>Gadofosveset</td>
<td>Gadoxetic acid</td>
</tr>
<tr>
<td></td>
<td>Gadopentetate dimeglumine</td>
<td></td>
</tr>
<tr>
<td>Nonionic</td>
<td>Gadoteridol</td>
<td>Gadodiamide</td>
</tr>
<tr>
<td></td>
<td>Gadobutrol</td>
<td>Gadoversetamide</td>
</tr>
</tbody>
</table>

Red—group I agents: associated with the greatest number of cases of nephrogenic systemic fibrosis

Green—group II agents: associated with few cases

Yellow—group III agents: data are limited, but few unconfirmed cases have been reported
### TABLE 4

**Key points from the ACR Manual on Contrast Media regarding prevention of nephrogenic systemic fibrosis in patients at risk**

<table>
<thead>
<tr>
<th>Kidney function</th>
<th>Recommendation</th>
<th>Authors’ comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chronic kidney disease stage 1 and 2</strong></td>
<td>No increased risk of developing NSF. Any gadolinium-based agent can be given safely.</td>
<td>There are no cases reported in this category with any of the gadolinium-based agents.</td>
</tr>
<tr>
<td><strong>Chronic kidney disease stage 3</strong></td>
<td>The risk of developing NSF is exceedingly rare. No special precautions are necessary.</td>
<td>There have been no definite cases reported in patients with stage 3 chronic kidney disease.</td>
</tr>
<tr>
<td><strong>Chronic kidney disease stage 4 and 5 not on chronic dialysis</strong></td>
<td>Group I agents are contraindicated. If a gadolinium-enhanced MRI study is to be done, a group II agent should be used.</td>
<td>Given the risk of CI-AKI in this population, we believe that MRI using a group II agent would be preferable to CT with iodinated contrast.</td>
</tr>
<tr>
<td><strong>End-stage kidney disease on hemodialysis</strong></td>
<td>The ACR favors CT rather than MRI if the anticipated diagnostic yield is similar. Group I agents are contraindicated. Group II agents are preferred and gadolinium-enhanced MRI should be performed as closely before hemodialysis as is possible.</td>
<td>We urge caution in dialysis patients with residual kidney function, which is associated with a survival benefit. We lean toward MRI with group II agents. Our current practice is to perform a single dialysis session rather than 2 consecutive sessions.</td>
</tr>
<tr>
<td><strong>End-stage kidney disease on peritoneal dialysis</strong></td>
<td>The ACR favors CT when possible, but if MRI is desired, then the ACR recommends a group II agent. The ACR recognizes that peritoneal dialysis may provide less NSF risk reduction than hemodialysis.</td>
<td>We urge caution in dialysis patients with residual kidney function, which is associated with a survival benefit. We lean toward MRI with group II agents. The committee does not comment on the necessity of subjecting these patients to hemodialysis. We believe it is safer to perform a single session of hemodialysis, particularly for peritoneal dialysis patients with no residual kidney function.</td>
</tr>
<tr>
<td><strong>Acute kidney injury</strong></td>
<td>Group I agents should be avoided in patients with known or suspected acute kidney injury. Group II agents are preferred.</td>
<td>We favor a stratified approach: Acute kidney injury on dialysis: As in patients with end-stage kidney disease, we recommend a single session of dialysis following gadolinium exposure. Nonoliguric acute kidney injury not on dialysis: Similar to advanced chronic kidney disease, if a gadolinium-enhanced MRI study is needed, a group II agent should be used. Oliguric acute kidney injury not on dialysis: We favor avoiding administration of gadolinium if possible. Otherwise, our practice is to perform a single hemodialysis session.</td>
</tr>
</tbody>
</table>

ACR = American College of Radiology; CI-AKI = contrast-induced acute kidney injury; CT = computed tomography; MRI = magnetic resonance imaging; NSF = nephrogenic systemic fibrosis.

Based on information in reference 41.
association of Radiologists all permit the use of group II gadolinium-based contrast agents in patients with advanced kidney disease. The American College of Radiology defines patients at risk of NSF as those: • With advanced chronic kidney disease (eGFR < 30 mL/min/1.73 m² not on dialysis) • On dialysis (any form) • With acute kidney injury.

In these patients, group I and III gadolinium-based contrast agents are contraindicated, with the caveat that there is insufficient real-life data to determine the risk of NSF from administration of group III agents. In patients at risk, if a gadolinium-enhanced MRI study is to be performed, a group II agent should be used. The lowest dose required to obtain the needed clinical information should be used, and it should generally not exceed the recommended single dose.

A summary of those recommendations with our comments and opinions is provided in Table 4.

Gadolinium—the end of the story?

Although NSF has been basically eradicated since the guidelines were implemented, several cases of NSF have been reported in patients who never were exposed to gadolinium. In a review of biopsy-proven cases of NSF reported in 98 articles, 27 (8%) of 325 patients had no clear exposure to these agents, and in the review of 639 biopsy-proven cases discussed above, 14 (2%) did not. This suggests that gadolinium-based contrast agents are a major trigger for NSF, but they may not be the only one. Time will tell if indeed other triggers have yet to be discovered.

Additionally, in recent years, there have been data suggesting that gadolinium can deposit in the brain after repeated exposure to gadolinium-based contrast agents, even in patients with healthy kidneys. This finding was confirmed histologically and has led to the birth of a new term to describe it: *gadolinium deposition disease*. The significance of this brain deposition remains unknown, and to date, no adverse health effects have been uncovered. However, the FDA published a safety alert in 2015 indicating the active investigation of the risk and clinical significance of these gadolinium deposits. The recent position statement of the American College of Radiology also recognizes this phenomenon and states, “Until we fully understand the mechanisms involved and their clinical consequences, the safety and tissue deposition potential of all [gadolinium-based contrast agents] must be carefully evaluated.”

It thus appears that we haven’t heard the last of gadolinium-based contrast agent-related disease. Additional research will be needed to understand the potential consequences of the use of these agents.

### REFERENCES

14. McDonald JS, McDonald RJ, Carter RE, Katzberg RW, Kallmes DF, Williamson EE. Risk of intravenous contrast material-mediated acute kidney injury: a propensity score-matched study stratified
37. US Food and Drug Administration. FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings. Accessed September 10, 2020. https://www.fda.gov/media/109825/download


Address: Ali Mehdi, MD, Department of Nephrology and Hypertension, Q7, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; mehdia@ccf.org